18:47:06 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning SPEC 0.00 SEK
2024-05-16 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-17 Ordinarie utdelning SPEC 0.00 SEK
2023-05-16 Kvartalsrapport 2023-Q1
2023-05-16 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-13 Ordinarie utdelning SPEC 0.00 SEK
2022-05-12 Kvartalsrapport 2022-Q1
2022-05-12 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-19 Ordinarie utdelning SPEC 0.00 SEK
2021-05-18 Årsstämma 2021
2021-05-18 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-29 Ordinarie utdelning SPEC 0.00 SEK
2020-05-28 Extra Bolagsstämma 2020
2020-05-28 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning SPEC 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-23 Kvartalsrapport 2019-Q1
2019-02-15 Bokslutskommuniké 2018
2018-11-06 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning SPEC 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-23 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning SPEC 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-23 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-25 Extra Bolagsstämma 2016
2016-11-03 Kvartalsrapport 2016-Q3
2016-08-22 Kvartalsrapport 2016-Q2
2016-05-19 Ordinarie utdelning SPEC 0.00 SEK
2016-05-18 Årsstämma 2016
2016-05-17 Kvartalsrapport 2016-Q1
2016-02-25 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
SpectraCure är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av medicintekniska system som används för behandling av prostatacancer. Cancer­­­behandlingarna utgår ifrån egenutvecklade system som avger laserljus­­källor och foto­reaktiva läkemedel, en behandlings­­metodik som används för invärtes solida tumörer av olika slag. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Lund.
2023-02-23 10:00:00
The regulatory authorities in Sweden have approved SpectraCure's clinical study of a new treatment for patients who suffer from prostate cancer recurrence. The recruitment of patients at Skåne University Hospital in Malmö is intended to start in March.

SpectraCure has previously signed an agreement with Skåne University Hospital regarding participation in the company's clinical study. The Swedish Medicines Agency and the Ethics Review Authority have approved the study. The study includes patients who have prostate cancer recurrence after previously undergoing radiotherapy. Recruitment of patients is intended to begin in March. The doctor responsible for the study is Anders Bjartell, a professor and senior physician at Skåne University Hospital. Co-examiner is Ymir Saemundsson, a urologist at Skåne University Hospital.

"We look forward to participating in the study and starting patient recruitment. In the future, we hope that SpectraCure's treatment will become an effective treatment option for patients suffering from prostate cancer recurrence," says Anders Bjartell.

Other hospitals that are a part of the study and where recruitment is ongoing are Princess Margaret Cancer Center in Toronto, University College London Hospital in London, and Memorial Sloan Kettering Cancer Center in New York. The study aims to investigate whether the treatment interstitial PDT with SpectraCure's Q-PRO® system and the light-activated drug verteporfin is a safe and effective treatment for prostate cancer recurrence.

Treatment of local recurrence in prostate cancer after radiotherapy is still controversial as many treatments cause serious side effects[1]. SpectraCure has developed a new medical device, Q-PRO®, with the potential to offer patients with recurred prostate cancer a focal treatment with few side effects. 

For further information: 
SpectraCure AB (publ) Masoud Khayyami, Acting CEO
E-mail: ir@spectracure.com
Website: www.spectracure.com


SpectraCure is developing a treatment system for the elimination of internal solid cancer tumours. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system, Q-PRO®, consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, and safe for every patient. The goal is that in addition to being tumour free, the patients will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system. 

The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, and trades under the short name SPEC.

[1] Valle, L. F., Lehrer, E. J., Markovic, D., Elashoff, D., Levin-Epstein, R., Karnes, R. J., Reiter, R. E., Rettig, M., Calais, J., Nickols, N. G., Dess, R. T., Spratt, D. E., Steinberg, M. L., Nguyen, P. L., Davis, B. J., Zaorsky, N. G., & Kishan, A. U. (2021). A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European urology, 80(3), 280–292. https://doi.org/10.1016/j.eururo.2020.11.010